Galderma has launched Restylane Defyne and Restylane Refyne, the first Optimal Balance Technology (OBT)–based hyaluronic acid injectables authorised in Japan.

• Product Details: Restylane Defyne and Refyne are designed for injection into the mid-to-deep dermis to correct moderate-to-severe facial wrinkles and folds.
• Portfolio Expansion: The Restylane portfolio in Japan now includes four products with the addition of Defyne and Refyne.
  
• Strategic Growth: These launches support Galderma’s growth strategy in Japan and the Asia Pacific region.

This summary is based on a report from BioSpectrum Asia and related press releases.